Funding
← Back to your selection

Venrock Healthcare Capital Partners

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Healthtech · Jan 1, 2026
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$395M
2 disclosed · full round size, not this investor’s share

By stage

Series A1
Series C+1

By primary sector

Biotech2

By country

United Kingdom1
United States1

Rounds

2 in this selection
CellCentric

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries D
Role not disclosed